Even With A 27% Surge, Cautious Investors Are Not Rewarding Windlas Biotech Limited's (NSE:WINDLAS) Performance Completely
Jun 07
Indian (NIFTY) Clinical Research and Equipment Industry Analysis
UpdatedJun 12, 2024
DataAggregated Company Financials
Companies15
- 7D5.1%
- 3M21.2%
- 1Y20.4%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has risen 5.0%, driven by gains from Divi's Laboratories of 3.5%. This takes the industry's 12 month performance to a gain of 23%. Earnings are forecast to grow by 22% annually.
Industry Valuation and Performance
Has the Indian Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 12 Jun 2024 | ₹1.7t | ₹194.5b | ₹21.5b | 33.4x | 80.7x | 8.9x |
| Fri, 10 May 2024 | ₹1.4t | ₹168.0b | ₹18.7b | 28.5x | 74.5x | 8.3x |
| Sun, 07 Apr 2024 | ₹1.4t | ₹168.5b | ₹18.6b | 28.6x | 76.7x | 8.5x |
| Tue, 05 Mar 2024 | ₹1.4t | ₹168.5b | ₹18.6b | 32.2x | 72.8x | 8x |
| Thu, 01 Feb 2024 | ₹1.4t | ₹166.5b | ₹19.0b | 31.3x | 74.4x | 8.5x |
| Sat, 30 Dec 2023 | ₹1.4t | ₹155.9b | ₹18.1b | 21.6x | 78.2x | 9.1x |
| Mon, 27 Nov 2023 | ₹1.4t | ₹155.9b | ₹18.1b | 22.6x | 77x | 8.9x |
| Wed, 25 Oct 2023 | ₹1.3t | ₹156.1b | ₹19.8b | 23.9x | 65.2x | 8.3x |
| Fri, 22 Sep 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 24.9x | 71.1x | 9.1x |
| Sun, 20 Aug 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 26.6x | 70.2x | 8.9x |
| Tue, 18 Jul 2023 | ₹1.4t | ₹156.5b | ₹23.0b | 30.9x | 59.6x | 8.8x |
| Thu, 15 Jun 2023 | ₹1.3t | ₹157.2b | ₹23.0b | 27.8x | 56.6x | 8.3x |
| Sat, 13 May 2023 | ₹1.2t | ₹163.0b | ₹28.6b | 33.7x | 43.3x | 7.6x |
| Mon, 10 Apr 2023 | ₹1.1t | ₹159.5b | ₹28.4b | 32.4x | 38.6x | 6.9x |
| Wed, 08 Mar 2023 | ₹1.1t | ₹159.5b | ₹28.4b | 31.5x | 37.7x | 6.7x |
| Fri, 03 Feb 2023 | ₹1.2t | ₹166.4b | ₹34.5b | 29x | 34x | 7.1x |
| Sun, 01 Jan 2023 | ₹1.2t | ₹164.9b | ₹34.5b | 30.9x | 35.5x | 7.4x |
| Tue, 29 Nov 2022 | ₹1.2t | ₹164.9b | ₹34.5b | 29.9x | 35.5x | 7.4x |
| Thu, 27 Oct 2022 | ₹1.3t | ₹164.1b | ₹36.1b | 35.7x | 35.4x | 7.8x |
| Sat, 24 Sep 2022 | ₹1.3t | ₹162.5b | ₹35.7b | 37.3x | 35.7x | 7.9x |
| Mon, 22 Aug 2022 | ₹1.3t | ₹162.6b | ₹35.8b | 37.1x | 36.4x | 8x |
| Wed, 20 Jul 2022 | ₹1.3t | ₹158.3b | ₹34.2b | 33.4x | 38.7x | 8.4x |
| Fri, 17 Jun 2022 | ₹1.2t | ₹158.3b | ₹34.2b | 32x | 36.3x | 7.8x |
| Sun, 15 May 2022 | ₹1.4t | ₹149.7b | ₹30.1b | 32.9x | 47.4x | 9.5x |
| Tue, 12 Apr 2022 | ₹1.6t | ₹148.3b | ₹29.4b | 38.3x | 53.3x | 10.6x |
| Thu, 10 Mar 2022 | ₹1.4t | ₹148.3b | ₹29.4b | 35.1x | 49.2x | 9.7x |
| Sat, 05 Feb 2022 | ₹1.5t | ₹138.5b | ₹24.5b | 38.6x | 60.5x | 10.7x |
| Mon, 03 Jan 2022 | ₹1.6t | ₹137.8b | ₹24.6b | 34.1x | 65.1x | 11.6x |
| Wed, 01 Dec 2021 | ₹1.6t | ₹137.6b | ₹24.4b | 30x | 67.5x | 12x |
| Fri, 29 Oct 2021 | ₹1.7t | ₹132.1b | ₹22.7b | 23.1x | 73x | 12.5x |
| Sun, 26 Sep 2021 | ₹1.7t | ₹131.1b | ₹22.9b | 23.8x | 73.7x | 12.9x |
| Tue, 24 Aug 2021 | ₹1.6t | ₹131.4b | ₹22.9b | 22.2x | 69.8x | 12.2x |
| Wed, 30 Jun 2021 | ₹1.5t | ₹127.1b | ₹22.6b | 36.9x | 65.2x | 11.6x |
Price to Earnings Ratio
65.2x
Current Industry PE
- Investors are optimistic on the Indian Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 80.2x which is higher than its 3-year average PE of 56.7x.
- The industry is trading close to its 3-year average PS ratio of 9.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 15% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Comparison
How does Indian Clinical Research and Equipment compare with similar industries?
| IN Market | 8.04% | |
| Healthcare | 6.51% | |
| Life Sciences | 5.13% | |
| Clinical Research and Equipment | 5.13% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| INDGN Indegene | ₹583.35 | 10.4% +₹12.3b | n/a | PE38.5x | |
| SYNGENE Syngene International | ₹694.55 | 3.4% +₹9.1b | -6.6% | PE54.2x | |
| 530239 Suven Life Sciences | ₹99.97 | 14.6% +₹2.8b | 58.2% | PS186.4x | |
| TARSONS Tarsons Products | ₹459.55 | 11.8% +₹2.6b | -17.3% | PE57.9x | |
| DCAL Dishman Carbogen Amcis | ₹165.15 | 10.4% +₹2.4b | 28.8% | PS1x |